Catalyst
Slingshot members are tracking this event:
FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ATRA |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 29, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tabelecleuce, Rituximab, Lymphoproliferative Disorder
